---
figid: PMC5824910__10.1177_1758834018757175-fig1
figtitle: G-alpha signaling pathway in uveal melanoma
organisms:
- NA
pmcid: PMC5824910
filename: 10.1177_1758834018757175-fig1.jpg
figlink: /pmc/articles/PMC5824910/figure/fig1-1758834018757175/
number: F1
caption: 'G-alpha signaling pathway in uveal melanoma (adapted from Patel M et al.
  Clin Cancer Res 2011; 17(8): 2087–2100). G-protein coupled receptors (GPCR) signal
  through the heterotrimeric proteins, Gα and Gβγ. Mutations in GNAQ or GNA11 lead
  to constitutive activation of Gα and downstream stimulation of the mitogen-activated
  protein kinase (MAPK) pathway via phospholipase C (PLCβ) and protein kinase C (PKC).
  The phosphotidylinositol-3 kinase (PI3K)/Akt/mTOR and the Yes-activated protein
  (YAP) pathways are also activated. All three signaling pathways contribute to tumor
  growth and proliferation. Targeted therapy against various downstream effectors
  have had limited clinical efficacy. ORR - overall response rate; PFS - progression-free
  survival.'
papertitle: 'Treatment of uveal melanoma: where are we now?.'
reftext: Jessica Yang, et al. Ther Adv Med Oncol. 2018;10:1758834018757175.
year: '2018'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9701616
figid_alias: PMC5824910__F1
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC5824910__F1
ndex: c9d4e6e5-dec8-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5824910__10.1177_1758834018757175-fig1.html
  '@type': Dataset
  description: 'G-alpha signaling pathway in uveal melanoma (adapted from Patel M
    et al. Clin Cancer Res 2011; 17(8): 2087–2100). G-protein coupled receptors (GPCR)
    signal through the heterotrimeric proteins, Gα and Gβγ. Mutations in GNAQ or GNA11
    lead to constitutive activation of Gα and downstream stimulation of the mitogen-activated
    protein kinase (MAPK) pathway via phospholipase C (PLCβ) and protein kinase C
    (PKC). The phosphotidylinositol-3 kinase (PI3K)/Akt/mTOR and the Yes-activated
    protein (YAP) pathways are also activated. All three signaling pathways contribute
    to tumor growth and proliferation. Targeted therapy against various downstream
    effectors have had limited clinical efficacy. ORR - overall response rate; PFS
    - progression-free survival.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - FZD4
  - NMUR1
  - LPAR3
  - LGR6
  - MRGPRX3
  - MRGPRX4
  - GPR151
  - OXER1
  - GPRC6A
  - MRGPRX1
  - VN1R17P
  - GPR166P
  - GRM1
  - GRM2
  - GRM3
  - GRM4
  - GRM5
  - GRM6
  - GRM7
  - GRM8
  - CASR
  - GABBR1
  - GABBR2
  - GPR156
  - GPR158
  - GPR179
  - GPRC5A
  - GPRC5B
  - GPRC5C
  - GPRC5D
  - PLCB1
  - PLCB2
  - PLCB3
  - PLCB4
  - MTG1
  - PRRT2
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - PRKCG
  - PRKCH
  - PRKCI
  - PRKCQ
  - PRKCZ
  - PRKD3
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - NPY6R
  - GNAQ
  - PTEN
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - TRIO
  - ACTA1
  - ACTA2
  - ACTB
  - ACTC1
  - ACTG1
  - ACTG2
  - AKT1
  - RAC1
  - RAC2
  - RAC3
  - RHOG
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - AKT2
  - AKT3
  - RHO
  - RHOD
  - RHOA
  - RHOB
  - RHOC
  - AMOT
  - EPHB2
  - MAPK1
  - MAPK3
  - YAP1
  - MTOR
  - AEBO71
  - BYL719
  - Ga
  - GDP
  - Trametinib
  - Selumetinib
  - Cancer
---
